title: Patients receiving androgen deprivation therapy for prostate cancer have an increased risk of depressive disorder.
abstract: Androgen deprivation therapy (ADT) results in testosterone suppression, a hypothesized mechanism linking ADT to depressive symptoms. This study investigated the relationship between ADT and the risk of subsequently being diagnosed with depressive disorder (DD) during a 3-year follow-up period. The patient sample for this population-based, retrospective cohort study was retrieved from the Taiwan Longitudinal Health Insurance Database 2005. We included all 1714 patients aged over 40 years with a first-time diagnosis of prostate cancer (PC) during 2001 to 2010 who did not have an orchiectomy. Among them, we defined 868 patients who received ADT during the 3-year follow-up period as the study group, and 846 patients who did not receive ADT as the comparison group. The incidence rates of DD per 1000 person-years were 13.9 (95% confidence interval (CI): 9.5~19.6) and 6.7 (95% CI: 3.7~11.0), respectively. Cox proportional hazard regressions showed that the adjusted hazard ratio for DD for ADT recipients was 1.93 (95% CI: 1.03~3.62) relative to the comparison group. This study presents epidemiological evidence of an association between ADT and a subsequent DD diagnosis.
authors.affiliation: Division of Urology, Department of Surgery, Far Eastern Memorial Hospital, Banciao, Taipei, Taiwan.|Graduate Program in Biomedical Informatics, College of Informatics, Yuan-Ze University, Chungli, Taiwan.|Research Center of Sleep Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
authors.forename: Shiu-Dong
authors.initials: SD
authors.lastname: Chung
authors.affiliation: Research Center of Sleep Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.|Graduate Institute of Life Science, National Defense Medical Center, Taipei, Taiwan.
authors.forename: Li-Ting
authors.initials: LT
authors.lastname: Kao
authors.affiliation: Research Center of Sleep Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.|School of Health Care Administration, Taipei Medical University, Taipei, Taiwan.
authors.forename: Herng-Ching
authors.initials: HC
authors.lastname: Lin
authors.affiliation: Department of Health Services Policy and Management, Arnold School of Public Health, University of South Carolina, Columbia, United States of America.
authors.forename: Sudha
authors.initials: S
authors.lastname: Xirasagar
authors.affiliation: School of Health Care Administration, Taipei Medical University, Taipei, Taiwan.
authors.forename: Chung-Chien
authors.initials: CC
authors.lastname: Huang
authors.affiliation: Research Center of Sleep Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.|Department of Psychiatry, Taipei Medical University-Shuang-Ho Hospital, Taipei, Taiwan.|Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University.
authors.forename: Hsin-Chien
authors.initials: HC
authors.lastname: Lee
mesh_terms: D000328:Adult; D000368:Aged; D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D016022:Case-Control Studies; D003866:Depressive Disorder / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013624:Taiwan
chemical_list: D000726:Androgen Antagonists